Trial Profile
A phase 2a clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of pGA2/JS7 DNA and MVA/HIV62, or of MVA/HIV62 alone, in healthy, HIV uninfected vaccinia-naive adult participants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs GOVX-B11 (Primary) ; MVA-HIV62 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms HVTN 205
- 20 Mar 2015 A follow-up study to this trial, in which patients are given a protein boost to evaluate their immune responses, is expected to be initiated in late 2015, according to a GeoVax media release.
- 09 Oct 2013 Additional results have been presented at the 2013 AIDS Vaccine Meeting according to a GeoVax Labs media release. Results were also reported in the media release.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed.